Emergex’s dengue vaccine candidate receives regulatory approval for its first phase clinical trial

UK – A company tackling major global infectious disease threats through the development of 100% synthetic ‘set point’ vaccines, Emergex Vaccines Holding has received regulatory approval for its phase 1 clinical trials of its Dengue Vaccine, pepGNP-Dengue. With approval from Swiss regulatory agencies, Emergex is set to enroll its first participants for the trial phase. The naNO-DENGUE phase 1 trials will evaluate Emergex’s novel T-Cell priming vaccine, which has been designed to deliver broad and long-lasting immunity by priming the body’s T-Cell response to provide rapid clearance of infected cells…

Read More

Technology takes center stage as companies and governments strive to digitize healthcare

WORLD – As the world goes digital and technology continues to advance, integration of vital services into the digital world is also taking shape and healthcare is top in the list as at current owing to the pandemic. According to a report by Grand View research, the global digital health market size was valued at USD 96.5 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028. The report also noted that, increasing cases of obesity, high prevalence of…

Read More